Literature DB >> 27816297

Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.

Mieke Van Hemelrijck1, Hans Garmo2, Lars Lindhagen3, Ola Bratt4, Pär Stattin5, Jan Adolfsson6.   

Abstract

BACKGROUND: Active surveillance (AS) is commonly used for men with low-risk prostate cancer (PCa). When life expectancy becomes too short for curative treatment to be beneficial, a change from AS to watchful waiting (WW) follows. Little is known about this change since it is rarely documented in medical records.
OBJECTIVE: To model transition from AS to WW and how this is affected by age and comorbidity among men with very low-risk PCa. DESIGN, SETTING, AND PARTICIPANTS: National population-based healthcare registers were used for analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using data on PCa characteristics, age, and comorbidity, a state transition model was created to estimate the probability of changes between predefined treatments to estimate transition from AS to WW. RESULTS AND LIMITATIONS: Our estimates indicate that 48% of men with very low-risk PCa starting AS eventually changed to WW over a life course. This proportion increased with age at time of AS initiation. Within 10 yr from start of AS, 10% of men aged 55 yr and 50% of men aged 70 yr with no comorbidity at initiation changed to WW. Our prevalence simulation suggests that the number of men on WW who were previously on AS will eventually stabilise after 30 yr. A limitation is the limited information from clinical follow-up visits (eg, repeat biopsies).
CONCLUSIONS: We estimated that changes from AS to WW become common among men with very low-risk PCa who are elderly. This potential change to WW should be discussed with men starting on AS. Moreover, our estimates may help in planning health care resources allocated to men on AS, as the transition to WW is associated with lower demands on outpatient resources. PATIENT
SUMMARY: Changes from active surveillance to watchful waiting will become more common among men with very low-risk prostate cancer. These observations suggest that patients need to be informed about this potential change before they start on active surveillance.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Comorbidity; Prostate cancer; Watchful waiting

Mesh:

Year:  2016        PMID: 27816297     DOI: 10.1016/j.eururo.2016.10.031

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

Review 1.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 2.  When and How Should Active Surveillance for Prostate Cancer be De-Escalated?

Authors:  Pawel Rajwa; Preston C Sprenkle; Michael S Leapman
Journal:  Eur Urol Focus       Date:  2020-02-02

Review 3.  Clinical and pathologic factors predicting reclassification in active surveillance cohorts.

Authors:  Pablo S Sierra; Shivashankar Damodaran; David Jarrard
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

4.  How to measure temporal changes in care pathways for chronic diseases using health care registry data.

Authors:  Eugenio Ventimiglia; Mieke Van Hemelrijck; Lars Lindhagen; Pär Stattin; Hans Garmo
Journal:  BMC Med Inform Decis Mak       Date:  2019-05-30       Impact factor: 2.796

5.  Factors that influence clinicians' decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study.

Authors:  Lisa M Lowenstein; Noah J Choi; Karen E Hoffman; Robert J Volk; Stacy Loeb
Journal:  BMJ Open       Date:  2021-11-12       Impact factor: 2.692

6.  No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance.

Authors:  Karolina Cyll; Sven Löffeler; Birgitte Carlsen; Karin Skogstad; May Lisbeth Plathan; Martin Landquist; Erik Skaaheim Haug
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

7.  Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.

Authors:  Eugenio Ventimiglia; Anna Bill-Axelson; Ola Bratt; Francesco Montorsi; Pär Stattin; Hans Garmo
Journal:  JAMA Netw Open       Date:  2022-09-01

8.  Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study.

Authors:  Jan Herden; Andreas Schwarte; Thorsten Werner; Uwe Behrendt; Axel Heidenreich; Lothar Weissbach
Journal:  World J Urol       Date:  2020-09-30       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.